GlassScriptPhysician profile
Myra T Howard
NPI 1801957105
$4,454.41
in general payments reported to CMS, 2019-2025
24 companies · $733 in 2025
The $733 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $829 · 2022: $710 · 2023: $1,150 · 2024: $1,033 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.23 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $489.95 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Gilead Sciences, INC. | $459.39 | 2023-2025 | Yeztugo, Epclusa, Descovy |
| Sanofi-Aventis U.S. LLC | $416.33 | 2022-2024 | |
| Amgen INC. | $257.31 | 2025 | Krystexxa |
| Abbott Laboratories | $198.72 | 2021-2023 | Infinity |
| Lilly USA, LLC | $191.14 | 2022-2024 | Mounjaro |
| Silk Road Medical, INC. | $163.69 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Novo Nordisk INC | $136.36 | 2022-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $133.51 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $129.77 | 2024 | Onpattro |
| Inspire Medical Systems, INC. | $121.29 | 2023 | Inspire |
| Teva Pharmaceuticals USA, INC. | $120.42 | 2025 | |
| Genzyme Corporation | $118.87 | 2023 | |
| Scynexis, INC. | $115.49 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $108.28 | 2021 | |
| Argenx US, INC. | $104.05 | 2024 | Vyvgart |
| Biogen, INC. | $94.06 | 2024 | Zurzuvae |
| Sage Therapeutics, LLC | $92.87 | 2025 | |
| Janssen Pharmaceuticals, INC | $75.62 | 2021 | |
| Exact Sciences Corporation | $34.69 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $25.25 | 2022 | |
| Organon LLC | $17.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.49 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.